Deamidated gliadin peptides


(Fusion protein of 2 deamidated gliadin peptides)

500 µg 735 € available

Art. No. G006
Synonym Deamidated Gliadin Peptide – fusion protein
Molecular Weight 31 kDa
Source Recombinantly produced in E. coli
Purity > 95% (SDS-PAGE and Coomassie staining)
Appearance White lyophilized solid.
Description DGPx2 is a fusion protein of 2 different deamidated gliadin peptides, fused with a carrier protein to be used as antigen for the detection of antibodies specific for deamidated gliadin. (Dørum S. et al., J Proteome Res. 2009; 8:1748-55).
Reagents DGPx2 is lyophilized from a solution of ~50 mM NaH2PO4, pH 6.8.
Reconstitution Add at least the volume of H2O the protein is lyophilized from (see Certificate of Analysis) to the vial of lyophilized powder. Rotate vial gently until solid dissolves. After reconstitution the solution should be stored frozen in working aliquots.
Application The recombinant antigen is meant for solid (ELISA and immuno blot) and fluid phase diagnostic assays. The protein is bound by human type IgA and IgG (auto) antibodies.
Coating Dilute with your coating buffer to an appropriate concentration e.g. 1 μg/ml. Please notice that coating conditions have to be evaluated carefully.
Storage Store at ≤ -20°C. Store working aliquots at ≤ -20°C. Avoid repeated freezing and thawing.
Delivery is possible at ambient temperature
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.
Related Products G005 - DGPx4
G007 - DGPx1


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • World ADC London 2020

    02.03.2020 - 05.03.2020
    London, Great Britain

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA

  • Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland

  • 19th International Celiac Disease Symposium

    30.09.2021 - 03.10.2021
    Sorrento, Italy